

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423]

Final Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|---|
| Company | General |
| Biogen (omaveloxolone) | All Wales Inherited Metabolic Disease Service |
| Patient/carer groups | All Wales Therapeutics and Toxicology |
| Ataxia UK | Centre |
| Beacon | Allied Health Professionals Federation |
| Brain and Spine Foundation | Board of Community Health Councils in |
| Brain Charity | Wales |
| Cardiomyopathy UK | British National Formulary |
| Diabetes UK | Care Quality Commission |
| Gene People | • Department of Health - Northern Ireland |
| Genetic Alliance UK | Healthcare Improvement Scotland |
| Neurological Alliance | Medicines and Healthcare products |
| Scoliosis Support & Research | Regulatory Agency |
| South Asian Health Foundation | National Association of Primary Care |
| Specialised Healthcare Alliance | National Pharmacy Association |
| | Neurological Alliance of Scotland |
| Healthcare professional groups | NHS Confederation |
| Association of British Neurologists | Scottish Medicines Consortium |
| British Association of Neuroscience | Wales Neurological Alliance |
| Nurses | Welsh Government |
| British Geriatrics Society | Welsh Health Specialised Services |
| British Neuropathological Society | Committee |
| British Society for Blood and Marrow | Oxford Ataxia Centre |
| Transplantation | Paediatric Ataxia Centre, National |
| British Society of Rehabilitation | Hospitals for Neurology and |
| Medicine | Neurosurgery |
| Chartered Society of Physiotherapy | Sheffield Children's Centre |
| Institute of Neurology | The London Ataxia Centre, National |
| National Neurosciences Advisory | Hospitals for Neurology and |
| Group | Neurosurgery |
| Primary Care and Community | The Sheffield Ataxia Centre, |
| Neurology Society | Department of Neurology, Royal |
| Royal College of General Practitioners | Hallamshire Hospital |
| Royal College of Nursing | |
| | Comparator companies |

Final stakeholder list for the evaluation of omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423] Issue date: October 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|---|
| Royal College of Occupational Therapists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England NHS Genomic Network of Excellence NHS Genomic Medicine Service | None <u>Relevant research groups</u> Brain Research UK Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Genomics England MRC Clinical Trials Unit National Hospital for Neurology and Neurosurgery National Institute for Health Research Oxford-Harrington Rare Disease Centre UCL Queen Square Institute of Neurology <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.